SAB-142
Protein Target: thymocytes, T-lymphocytes, CD4+ T cells, CD8+ T cells
SAB Biotherapeutics
Most recent annual filing: 2026-03-09
- SAB-142 enrollment done4Q 2026SAB-142 enrollment done, 4Q 2026, notable
- SAB-142 topline2H 2027SAB-142 topline, 2H 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Technology platforms
Tc-Bovine
Transchromosomic cattle platform using engineered human artificial chromosomes to produce targeted, multi-specific human IgG (hIgG) polyclonal antibodies at scale without human plasma donors; applicable to immune/autoimmune disorders, cancer, viruses, bacteria, and toxins
Biotech Distilled coverage (2)
- 2026-08-07 UPDATE: SAB Biotherapeutics (SABS) - The Herd Gets a Backup, the Float Gets a Haircut 🔒 Paid
- 2026-07-16 SAB Biotherapeutics (SABS) — Scientific Deep Dive for SAB-142 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.